THE USE OF ANTI-DKK1 MONOCLONAL ANTIBODY FOR TREATMENT OF LIVER CANCER
The invention provides a method of treating liver cancer comprising administering anti-DKK1 monoclonal antibody to a subject in need thereof. Anti-DKK1 monoclonal antibody can also be administered for preventing or ameliorating cancer metastasis and for neutralizing serum and tissue DKK1 in liver cancer patients. The use of anti-DKK1 monoclonal antibodies is based on the discovery of the upregulation of DKK1 in human liver cancer.
Inventor: NG LUI, Oilin, Irene | TUNG, Kwokkwan
Priority Number: WO2012103787A1
IPC Current: A61K0039395 | A61P003500
Assignee Applicant: The University of Hong Kong
Title: USE OF ANTI-DKK1 MONOCLONAL ANTIBODY FOR TREATMENT OF LIVER CANCER | UTILISATION D'UN ANTICORPS MONOCLONAL ANTI-DKK1 POUR LE TRAITEMENT DU CANCER DU FOIE
Usefulness: USE OF ANTI-DKK1 MONOCLONAL ANTIBODY FOR TREATMENT OF LIVER CANCER | UTILISATION D'UN ANTICORPS MONOCLONAL ANTI-DKK1 POUR LE TRAITEMENT DU CANCER DU FOIE
Summary: The method (M1) is useful for treating liver cancer and Wnt signaling-driven cancer by suppressing tumor cell migration, tumor metastasis and tumor growth in mammal (claimed).
Novelty: Treating liver cancer, involves obtaining serum sample from hepatocellular carcinoma patient, measuring serum Dickkopf-related protein 1 levels in serum sample, and administering anti-DKK1 monoclonal antibody to patient
診斷/治療
癌症/腫瘤
13/361,439
美國
